Learn more about the diseases against which KINRIX offers protection by clicking on one of the links below:
Diphtheria
Diphtheria is a bacterial respiratory disease that causes a thickening of throat tissues, and can lead to breathing problems, paralysis, heart failure, and even death.
The Advisory Committee on Immunization Practices (ACIP) recommends 5 doses of DTaP vaccine for infants and children, one each at the following ages: 2 months, 4 months, 6 months, 15-18 months, 4-6 years old. DTaP vaccine may be given at the same time as other vaccines.
Back to Top
Tetanus
Tetanus (lockjaw) enters the body through cuts, scratches, or wounds in the skin. Tetanus can cause muscle stiffness, painful muscle spasms, seizures, and even death. The painful tightening of the jaw muscles can prevent a person from opening their mouth or swallowing.
As with Diphtheria, the ACIP recommends 5 doses of DTaP, including one at the 4- to 6-year-old visit.
Back to Top
Pertussis
Pertussis (whooping cough) is a highly infectious illness that causes severe spells of coughing that may interfere with normal breathing. The coughing is often accompanied by a "whooping" sound, so pertussis is often called whooping cough. The cough may last for weeks. Pertussis can also cause pneumonia, seizures, brain damage, and even death.
Again, the ACIP recommends 5 doses of DTaP, including one at ages 4 to 6 years.
Back to Top
Polio
Poliomyelitis (polio) is a viral disease. In its most serious form, polio infection causes paralysis of the muscles, including those needed for breathing and walking. In some people it can cause permanent damage or even death.
ACIP recommends 4 doses of Inactivated Polio Vaccine (IPV), one at each of the following ages: 2 months, 4 months, 6 to 18 months, and booster dose at 4 to 6 years.
KINRIX combines DTaP and IPV vaccines, and can reduce the number of injections your child will need to meet the CDC recommended immunization schedule.
Back to Top
NEXT: Patient information Q&A
Ask your doctor if KINRIX is right for your child.
KINRIX is indicated for the fifth DTaP and fourth dose IPV in 4 to 6 year olds whose previous DTaP vaccine doses have been with INFANRIX and/or PEDIARIX.
Important Safety Information
In clinical studies, common adverse events were injection-site reactions (pain, redness, swelling, or increase in arm circumference), drowsiness, fever, and loss of appetite. Previous hypersensitivity to any component of KINRIX, including neomycin and polymyxin B, is a contraindication. Encephalopathy within 7 days of administration of a previous pertussis-containing vaccine or a progressive neurologic disorder is a contraindication. The decision to give KINRIX should be based on potential benefits and risks, if Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, or if adverse events have occurred in temporal relation to receipt of a pertussis-containing vaccine. The needleless, prefilled syringes contain dry natural latex rubber and may cause allergic reactions. For children at higher risk for seizures, an antipyretic may be administered at the time of vaccination. Vaccination with KINRIX may not protect all individuals who received the vaccine.
Download the Complete Prescribing Information for KINRIX
Download Patient Information for KINRIX
Infanrix® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed)
Pediarix® [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Combined]
KINRIX is a trademark of GlaxoSmithKline.
Manufactured by GlaxoSmithKline Biologicals, Rixensart, Belgium
Distributed by GlaxoSmithKline, Research Triangle Park, NC 27709
